Literature DB >> 27638360

In-host adaptation and acquired triazole resistance in Aspergillus fumigatus: a dilemma for clinical management.

Paul E Verweij1, Jianhua Zhang2, Alfons J M Debets2, Jacques F Meis3, Frank L van de Veerdonk4, Sijmen E Schoustra2, Bas J Zwaan2, Willem J G Melchers5.   

Abstract

Aspergillus fumigatus causes a range of diseases in human beings, some of which are characterised by fungal persistence. A fumigatus can persist by adapting to the human lung environment through physiological and genomic changes. The physiological changes are based on the large biochemical versatility of the fungus, and the genomic changes are based on the capacity of the fungus to generate genetic diversity by spontaneous mutations or recombination and subsequent selection of the genotypes that are most adapted to the new environment. In this Review, we explore the adaptation strategies of A fumigatus in relation to azole resistance selection and the clinical implications thereof for management of diseases caused by Aspergillus spp. We hypothesise that the current diagnostic tools and treatment strategies do not take into account the biology of the fungus and might result in an increased likelihood of fungal persistence in patients. Stress factors, such as triazole exposure, cause mutations that render resistance. The process of reproduction-ie, sexual, parasexual, or asexual-is probably crucial for the adaptive potential of Aspergillus spp. As any change in the environment can provoke adaptation, switching between triazoles in patients with chronic pulmonary aspergillosis might result in a high-level pan-triazole-resistant phenotype through the accumulation of resistance mutations. Alternatively, when triazole therapy is stopped, an azole-free environment is created that could prompt selection for compensatory mutations that overcome any fitness costs that are expected to accompany resistance development. As a consequence, starting, switching, and stopping azole therapy has the risk of selecting for highly resistant strains with wildtype fitness. A similar adaptation is expected to occur in response to other stress factors, such as endogenous antimicrobial peptides; over time the fungus will become increasingly adapted to the lung environment, thereby limiting the probability of eradication. Our hypothesis challenges current management strategies, and future research should investigate the genomic dynamics during infection to understand the key factors facilitating adaptation of Aspergillus spp.
Copyright © 2016 Elsevier Ltd. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2016        PMID: 27638360     DOI: 10.1016/S1473-3099(16)30138-4

Source DB:  PubMed          Journal:  Lancet Infect Dis        ISSN: 1473-3099            Impact factor:   25.071


  48 in total

Review 1.  Clinical implications of globally emerging azole resistance in Aspergillus fumigatus.

Authors:  Jacques F Meis; Anuradha Chowdhary; Johanna L Rhodes; Matthew C Fisher; Paul E Verweij
Journal:  Philos Trans R Soc Lond B Biol Sci       Date:  2016-12-05       Impact factor: 6.237

2.  Genomic characterization of recurrent mold infections in thoracic transplant recipients.

Authors:  Julia A Messina; Cameron R Wolfe; Marion Hemmersbach-Miller; Carmelo Milano; Jamie L Todd; John Reynolds; Barbara D Alexander; Wiley A Schell; Christina A Cuomo; John R Perfect
Journal:  Transpl Infect Dis       Date:  2018-06-19       Impact factor: 2.228

Review 3.  The Emerging Threat of Antifungal Resistance in Transplant Infectious Diseases.

Authors:  Ilan S Schwartz; Thomas F Patterson
Journal:  Curr Infect Dis Rep       Date:  2018-02-05       Impact factor: 3.725

Review 4.  Aspergillus fumigatus and aspergillosis: From basics to clinics.

Authors:  A Arastehfar; A Carvalho; J Houbraken; L Lombardi; R Garcia-Rubio; J D Jenks; O Rivero-Menendez; R Aljohani; I D Jacobsen; J Berman; N Osherov; M T Hedayati; M Ilkit; D James-Armstrong; T Gabaldón; J Meletiadis; M Kostrzewa; W Pan; C Lass-Flörl; D S Perlin; M Hoenigl
Journal:  Stud Mycol       Date:  2021-05-10       Impact factor: 16.097

Review 5.  Emerging Infections and Pertinent Infections Related to Travel for Patients with Primary Immunodeficiencies.

Authors:  Kathleen E Sullivan; Hamid Bassiri; Ahmed A Bousfiha; Beatriz T Costa-Carvalho; Alexandra F Freeman; David Hagin; Yu L Lau; Michail S Lionakis; Ileana Moreira; Jorge A Pinto; M Isabel de Moraes-Pinto; Amit Rawat; Shereen M Reda; Saul Oswaldo Lugo Reyes; Mikko Seppänen; Mimi L K Tang
Journal:  J Clin Immunol       Date:  2017-08-07       Impact factor: 8.317

6.  Antifungal Susceptibility of the Aspergillus viridinutans Complex: Comparison of Two In Vitro Methods.

Authors:  Pavlina Lyskova; Vit Hubka; Lucie Svobodova; Vanessa Barrs; Navneet K Dhand; Takashi Yaguchi; Tetsuhiro Matsuzawa; Yoshikazu Horie; Miroslav Kolarik; Radim Dobias; Petr Hamal
Journal:  Antimicrob Agents Chemother       Date:  2018-03-27       Impact factor: 5.191

Review 7.  Molecular Mechanisms of Conidial Germination in Aspergillus spp.

Authors:  Tim J H Baltussen; Jan Zoll; Paul E Verweij; Willem J G Melchers
Journal:  Microbiol Mol Biol Rev       Date:  2019-12-04       Impact factor: 11.056

8.  Elevated MIC Values of Imidazole Drugs against Aspergillus fumigatus Isolates with TR34/L98H/S297T/F495I Mutation.

Authors:  Yong Chen; Zongwei Li; Xuelin Han; Shuguang Tian; Jingya Zhao; Fangyan Chen; Xueting Su; Jingjun Zhao; Ziying Zou; Yanwen Gong; Fen Qu; Guangbin Qiu; Siyao Wang; Xiaodong Jia; Zhongyi Lu; Mandong Hu; Liuyu Huang; Paul E Verweij; Li Han
Journal:  Antimicrob Agents Chemother       Date:  2018-04-26       Impact factor: 5.191

Review 9.  Aspergillus fumigatus and Aspergillosis in 2019.

Authors:  Jean-Paul Latgé; Georgios Chamilos
Journal:  Clin Microbiol Rev       Date:  2019-11-13       Impact factor: 26.132

10.  Evolution of cross-resistance to medical triazoles in Aspergillus fumigatus through selection pressure of environmental fungicides.

Authors:  Jianhua Zhang; Joost van den Heuvel; Alfons J M Debets; Paul E Verweij; Willem J G Melchers; Bas J Zwaan; Sijmen E Schoustra
Journal:  Proc Biol Sci       Date:  2017-09-27       Impact factor: 5.349

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.